LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
New Fortress Energy
NFE
4
Hutchmed (China)
HCM
5
Lantheus
LNTH
US Stock MarketDetailed Quotes
MLTX MoonLake Immunotherapeutics
- 39.150
- -0.270-0.68%
Close Apr 28 16:00 ET
- 40.450
- +1.300+3.32%
Pre 04:57 ET
2.48BMarket Cap-20.71P/E (TTM)
40.335High38.670Low541.67KVolume39.900Open39.420Pre Close21.24MTurnover1.92%Turnover RatioLossP/E (Static)63.28MShares58.26052wk High5.54P/B1.10BFloat Cap31.42052wk Low--Dividend TTM28.21MShs Float64.980Historical High--Div YieldTTM4.22%Amplitude4.250Historical Low39.210Avg Price1Lot Size
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
MoonLake Immunotherapeutics Stock Forum
MoonLake Lands Massive $500M Deal: Game-Changing Clinical Updates Coming April 29
Gapping up
$Qorvo (QRVO.US)$ saw a 7% increase after reports of activist investor Starboard Value acquiring a 7.7% stake.
$MoonLake Immunotherapeutics (MLTX.US)$ gained over 4% following Goldman Sachs' upgrade to 'buy', citing positive expectations for its phase 3 trial data.
$Life360 (LIF.US)$ rose 3% following UBS's upgrade to 'buy', based on promising ad revenue potential.
$Rivian Automotive (RIVN.US)$ increased 2...
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
The short stock would be $MoonLake Immunotherapeutics (MLTX.US)$ It has just seen its highest run. Once it gets above 50.00 its loses investors interest.
No comment yet